Enterprise Value to EBITDA Ratio: iCAD Corp (ICAD)
This chart illustrating the EV/EBITDA valuation history for iCAD, Inc. (ICAD), a developer of cloud-based AI services for early breast cancer diagnosis, currently shows a level of . Management aims to scale the number of paid subscriptions by integrating its algorithms into the daily practice of physicians. The business relies on stable demand within the healthcare sector, which makes the asset resilient to global economic shocks and provides it with the status of a defensive tool.
Analytical breakdowns for iCAD, Inc.
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ICAD - Final Profit|Projected Future Earnings iCAD, Inc.|ICAD - Business Payback Period|Future Price to Earnings iCAD|ICAD - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple iCAD, Inc.|ICAD - Operating profit before deduction of amortization|Net earnings per share for the last 12 months iCAD|ICAD - Net earnings per share for the last four quarters|Quarterly EPS earnings growth icadmed.com|ICAD - Expected net earnings per share growth this year|Earnings growth forecast for next year iCAD, Inc.
Analysis of all company metrics:iCAD Corp ICAD
Investors are evaluating iCAD, Inc. (ICAD) through the lens of debt sustainability and cash flow generation capabilities. This ratio compares the enterprise value, including net debt, to EBITDA, measuring the payback period of the assets. By analyzing the current EV/EBITDA multiple of the business, one can understand how the cloud-based cancer diagnostics infrastructure impacts the capitalization and overall fundamental value of the company.
Competitors of iCAD, Inc.
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Total Company Value to Operating Income Before Depreciation Ratio delcath.com|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|AURA - Enterprise Value to EBITDA Ratio|Candel - EV/EBITDA Multiple|ARAY - EV/EBITDA Multiple|SLS: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ACTU|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TCRX: Enterprise Value to Operating Income Before Depreciation|Champions Oncology Corp - EV/EBITDA Multiple|XBiotech Inc. (XBIT) - Enterprise Value to EBITDA Ratio|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Artiva (ARTV) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANL|Enterprise Value to EBITDA Ratio Veru Inc VERU|EV/EBITDA Multiple TPST (Tempest Tx)|EV/EBITDA Multiple Xilio Therapeutics Inc XLO|Enochian BioSciences - EV/EBITDA Multiple|MURA (Mural Oncology plc) - Enterprise Value to Operating Income Before Depreciation|KAPA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|EV/EBITDA Multiple Curis Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|tharimmune.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ADVB (Advanced Biomed)|GNPX - Enterprise Value to EBITDA Ratio|Calidi Bio - EV/EBITDA Multiple|Company Value to EBITDA sunshinebiopharma.com|xeneticbio.com (XBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|salariuspharma.com - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio PPBT|AONC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BGNE|Enterprise Value to EBITDA Ratio Checkpoint Therapeutics Inc CKPT|Elevation Oncology - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
